Advanced Filters
noise

Carcinoma Clinical Trials

A listing of Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 6,070 clinical trials
D Debbie Nathan

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Background The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate gland. Many people now seek out focal therapy options to decrease the side effects of treatment. Until now, several forms of physical destruction with heat …

18 - 120 years of age Male Phase 2

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors

Primary objective: To determine the maximum tolerated dose and/or recommended dose for extension for IMA401 Secondary objectives: To characterize the safety and tolerability of IMA401 To evaluate initial anti-tumor activity of IMA401 To describe the pharmacokinetics of IMA401

18 years of age All Phase 1

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors. Primary objectives: To determine the maximum tolerated dose and/or recommended dose for extension for IMA402 (Phase I) To characterize the safety and tolerability of IMA402 …

18 years of age All Phase 1/2
J Jason Luke

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

The study purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).

18 years of age All Phase 1
F Flordeliza Mendoza

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

This is Phase 1 dose finding trial with potential dose expansion to evaluate the safety, toxicity, recommended phase 2 dose (RP2D), and maximum tolerated dose (MTD) of Neratinib plus TDxD using a standard 3+3 dose escalation design in patients with metastatic or unresectable gastro-esophageal cancer that are HER2-overexpressing (IHC 3+ …

18 years of age All Phase 1
G Geok H Lim

Omission of Axillary Surgery in Breast Cancer Patients

The treatment and prognosis of breast cancer (BC) are dependent on its molecular subtype and nodal burden. In early BCs with favourable molecular subtype, the incidence of axillary node involvement is low. However, these patients are still subjected to an axillary operation, which can result in additional cost, operating time …

21 - 80 years of age Female Phase N/A
M Margaret McNeely, PhD

Continence, Sexual Function, Fitness and the Health of Men After Surgery for Prostate Cancer

The Continence, Sexual and Metabolic Health (CONTROL 4 LIFE) study will evaluate the recovery of continence, sexual function, and health outcomes in individuals who have undergone surgery for prostate cancer. The purpose of this study is to better understand the timelines of recovery for these outcomes after surgery for prostate …

18 years of age Male Phase N/A
T Tania Fleitas, MD, PhD

Evaluation of Improvements in Patient-reported Quality of Life

Local intervention trial for the evaluation of improvements in patient-reported Quality of Life and treatment satisfaction, in breast cancer patients (BCP), as a result of flexible treatment planning supported by REBECCA-collected real-world data, in comparison with standard care

18 - 75 years of age Female Phase N/A
L Lisa Thibodeaux, RN BSN

THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation

The study's purpose is to evaluate whether creatine supplementation can help breast cancer survivors respond quicker to exercise by improving strength, endurance, and body composition. We are seeking to compare information collected from healthy woman of the same age who have never had breast cancer to those participants who have …

18 - 75 years of age Female Phase N/A
A Anand D Jeyasekharan

Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)

CAR-T is a pioneering cancer treatment which has found success in some cancers. This treatment is made first by taking blood cells from the patient. Then in the lab, an artificial protein - a Chimeric Antigen Receptor (CAR), is grafted on the surface of immune cells. The modified cells, which …

21 years of age All Phase 1

Simplify language using AI